anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The utility model relates to a cosmetic composition widely applicable in the cosmetic and / or pharmaceutical industry for manufacturing of lotions, creams, shampoos, soaps, products for treating various skin types, as well as separate application. According to the utility model, the cosmetic composition has been created and contains cold-pressed natural base oils from seeds of hybrid sunflower varieties (Helainthus Annuus L.) suitable for growing in the climatic conditions of Bulgaria and hip seeds (Rosa Canina, Rosa Cinnamomea, Rosa Rugosa) of cultivated Bulgarian varieties as well as cold-pressed natural base oils of cotton (Gossypium nirsutum) and Argania Spinosa. The natural base oil ingredients are blended in the following quantitative ratio: 40% wt sunflower oil, 20% wt. hip oil; 10% wt. cottonseed oil and 10% wt. Argan oil. The composition contains the following further components: 5% wt. tar, 5% wt. glycerine, 2% wt. panthenol and 8% wt. organic solvent. The advantage of the claimed cosmetic composition is that the components are selected in composition and ratio so as to provide the desired cosmetic effects. The use of the cold-pressing method to obtain the composition guarantees the cosmetic effects and the preservation of the beneficial healing properties of the ingredients. The cosmetic composition is perceived equally well by normal, dry, oily and problematic skins. It has a moisturizing, regenerating, softening and antiseptic effect. It soothes and protects the skin from harmful environmental effects. It further maintains and restores the water-lipid balance of the skin. It hydrates the skin in depth, improves elasticity and smooths scars and wrinkles. It effects regeneration on irritated, irritated or injured skin at acne and burns problems.
PURPOSE OF REVIEW: Kidney dysfunction is challenging in liver transplant candidates to determine whether it is reversible or not. This review focuses on the pertinent data on how to best approach liver transplant candidates with kidney dysfunction in the current era after implementing the simultaneous liver kidney (SLK) allocation policy and safety net.
RECENT FINDINGS: The implementation of the SLK policy inverted the steady rise in SLK transplants and improved the utilization of high-quality kidneys. Access to kidney transplantation following liver transplant alone (LTA) increased with favorable outcomes. Estimating GFR in liver transplant candidates remains challenging, and innovative methods are needed. SLK provided superior patient and graft survival compared to LTA only for patients with advanced CKD and dialysis at least 3 months. SLK can provide immunological protection against kidney rejection in highly sensitized candidates. Post-SLK transplant care is complex, with an increased risk of complications and hospitalization.
SUMMARY: The SLK policy improved kidney access and utilization. Transplant centers are encouraged, under the safety net, to reserve SLK for liver transplant candidates with advanced CKD or dialysis at least 3 months while allowing lower thresholds for highly sensitized patients. Herein, we propose a practical approach to liver transplant candidates with kidney dysfunction.
INTRODUCTION: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has been established as an effective treatment for peritoneal cancer (PC). However, this kind of combination therapy is associated with a high lactate level. Moreover, studies have suggested that the rate of complications early after surgery directly increased with elevated lactate levels. Glucose-insulin-potassium (GIP), a potent cardioprotective intervention, has been demonstrated to adjust blood glucose (BG) levels and reduce lactate levels. However, the insulin-glucose ratio should be adjusted according to the surgery performed. Here, we aimed to evaluate the advantages of using modified GIP during CRS/HIPEC to reduce the lactate level at the end of surgery and further reduce the incidence of early postoperative complications.
METHODS AND ANALYSIS: The modified GIP versus conventional management during surgery study is a single-center, randomized, single-blinded outcome assessment clinical trial of 80 patients with PC who are between 18 and 64 years old and undergoing CRS/HIPEC. Participants will be randomly allocated to receive modified GIP or conventional treatment (1:1). The primary outcome will be the plasma lactate level at the end of surgery. The secondary outcomes will include the highest levels and fluctuation ranges of lactate and BG during surgery, extubation time, APACHE-II score 24 h after surgery, postoperative defecation and exhaust time, postoperative lactate clearance time, postoperative liver and kidney function, incidence of complications within 7 days after surgery, length of intensive care unit stay (LIS), length of hospital stay (LHS), and total cost of hospitalization.
ETHICS AND DISSEMINATION: The trial protocol was approved by the Scientific Research Ethics Committee of Beijing Shijitan Hospital Affiliated with Capital Medical University, approval number sjtky11-1x-2022(118). The results will be published in international peer-reviewed journals.
TRIAL REGISTRATION: ChiCTR2200057258. Registered on March 5, 2022.
An adhesive patch for securing a transdermal device (Fig 3, 12) to the skin (fig 3, 10) comprises a double-sided adhesive layer 4. A permeable membrane element 2 is located in an aperture 20 in the adhesive layer. There is a small area of overlap 22 where the adhesive layer 4 adheres to the membrane element 2 to secure it against movement during application and use of the patch. The area of overlap may occupy less than 25% of the surface area of the membrane element and may overlap the membrane element at fewer than four positions or may overlap continuously. The membrane element may be formed from porous nylon and may permit the transport of molecules of an analyte that is to be sampled from the skin or molecules of a drug that is to be delivered to the skin. The lower surface of the adhesive layer may be releasably adherable to skin and the upper surface releasably adherable to a transdermal device.
R-ICEesc will be administered with the intent of administering 2 cycles, each 21 days apart admixed with 4 doses of rituximab. G-CSF will be administered at 960 ug or 10 ug/kg if patient is \> 100 kg after cycles one and two for PBPC collection for the first 10 patients enrolled. G-CSF will be administered in standard dosing for cycle one and then at 960 ug or 10 ug/kg (if patient is \> 100 kg) after cycle two for PBPC collection for the remaining 22 patients. All responding patients who make at least 2 x 106 CD34+ cells/kg will receive high dose therapy and ASCT on other protocols.
Disclosed is a 5' flanking sequence of the human fas gene containing a promoter region. This sequence also contains at least three transcription initiation sites, as well as consensus sequences for AP-1, GF-1, NY-Y, CP-2, EB20, and c-myb. Also disclosed are methods of altering senescence of the immune system by modifying Fas activity in cells to increase or decrease apoptosis. Fas expression and function on T cells from old (22-26-month-old) mice is also compared to young (2-month-old) mice and old CD2-fas transgenic mice. Fas expression and ligand-induced apoptosis was decreased on T cells from old mice compared to young mice. In 26-month-old CD2-fas transgenic mice, Fas and CD44 expression, Fas-induced apoptosis, T cell proliferation and cytokine production were comparable to that of the young mice. These results suggest that T cell senescence with age is associated with defective apoptosis and that the CD2-fas transgene allows the maintenance of Fas apoptosis function and T cell function in aged mice comparable to that of young mice.
PURPOSE: This study investigates how social categories work and intersect in siblings bereaved by drug-related deaths' (DRDs) stories about their relationships to their deceased brother or sister. The sociocultural embedded process of making meaning of the relationship with the deceased individual is essential in adapting to the loss. However, insight into such experiences of siblings bereaved by a DRD is scarce. Previous research has suggested that DRDs may be stigmatized life experiences for bereaved family members, and this paper furthers understanding of the experiences and issues involved in losing a sibling in a stigmatized death.
METHODS: An intersectional analysis is applied to interviews with 14 bereaved siblings. By investigating and displaying how different categories intertwine, various positionings are identified.
FINDINGS: Categorization of the deceased siblings as "addicts" constructs a troubled position. However, when "addict" intersects with the categories "unique," "sibling," and "uncle," the troubled subject's position as an "addict" can be concealed.
CONCLUSIONS: Normative conceptions of addiction and DRDs produce troubled subject positions. By intermingling the category of "addict" with other categories, less problematic positions are created. Still, intersections of categories can also construct further complexities of remorse and self-blame for the bereaved siblings.
OBJECTIVE: To investigate the mechanism of gastrodin for inhibiting microglia-mediated inflammation after hypoxicischemic brain damage (HIBD) in neonatal rats.
METHODS: Thirty-nine 3-day-old SD rats were randomly divided into sham group, HIBD group and gastrodin treatment group. Western blotting was used to detect the expressions of TNF-α, IL-1β, IL-10 and TGF- β1 in the corpus callosum of the rats. The potential targets of gastrodin for treatment of HIBD were screened by network pharmacology analysis. The expressions of PI3K/AKT signaling pathway proteins following HIBD-induced microglial activation in the rats and in cultured microglial BV-2 cells with oxygen-glucose deprivation (OGD) were detected with Western blotting. The effects of LY294002 (a specific inhibitor of the PI3K/AKT pathway) and gastrodin on TNF-α and TGF-β1 mRNA levels in BV-2 cells with OGD was detected with RT-qPCR.
RESULTS: In the neonatal rats with HIBD, gastrodin treatment significantly decreased TNF-α and IL-1β expressions and enhanced IL-10 and TGF-β1 expressions in the ischemic corpus callosum. Network pharmacology analysis showed significant enrichment of the PI3K/AKT signaling pathway and a strong binding between gastrodin and PI3K. Gastrodin significantly promoted PI3K and AKT phosphorylation in neonatal rats with HIBD and in BV-2 cells exposed to OGD. In BV-2 cells with OGD, gastrodin obviously suppressed OGD-induced increase of TNF-α and reduction of TGF-β1 mRNA expressions, and this effect was strongly attenuated by LY294002 treatment.
CONCLUSION: Gastrodin can inhibit microglia-mediated inflammation in neonatal rats with HIBD by regulating the PI3K/AKT signaling pathway.
Chronic liver disease (CLD) is a major global health burden in terms of growing morbidity and mortality. Although many conditions can cause CLD, leading to cirrhosis and hepatocellular carcinoma (HCC), viral hepatitis, drug-induced liver injury (DILI), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are the most common culprits. Prostaglandin E2 (PGE2), produced in the liver, is an important lipid mediator derived from the ω-6 polyunsaturated fatty acid, arachidonic acid, and plays a critical role in hepatic homeostasis. The physiological effects of PGE2 are mediated through four classes of E-type prostaglandin (EP) receptors, namely EP1, EP2, EP3 and EP4. In recent years, an increasing number of studies has been done to clarify the effects of PGE2 and EP receptors in regulating liver function and the pathogenesis of CLD to create a new potential clinical impact. In this review, we overview the biosynthesis and regulation of PGE2 and discuss the role of its synthesizing enzymes and receptors in the maintenance of normal liver function and the development and progress of CLD. We also discuss the potential of the PGE2-EP receptors system in treating CLD with various etiologies.
The present disclosure provides systems and methods for predicting attack types and likelihood the attack types will occur for new vulnerabilities. According to the present disclosure, the method includes receiving a disclosure of a new vulnerability, the disclosure comprising a plurality of vulnerability details. The method includes developing a series of vulnerability features associated with the details of the new vulnerability. The method includes extracting each of the vulnerability features into intermediate inputs. The method includes providing each of the intermediate inputs to one or more attack type classifiers to thereby determine if an attack type is associated with the new vulnerability. The method includes determining ranking for each of the one or more attacks occurring for the new vulnerability. The method finally includes assigning one or more attack type labels to the new vulnerability based on each attack type associated with the new vulnerability. Other aspects are also described.
BACKGROUND: The presence of ochratoxin A (OTA) in food and feed is a public health concern. OTA intoxication is caused by several mechanisms, one of which consists of the alteration of the antioxidant activity of the cell due to the oxidative stress (OS). In this context, the use of natural antioxidant substances could be a potential biological decontamination method of mitigating the negative outcomes induced by OTA.
METHODS: we aimed to investigate how a red orange and lemon extract (RLE), rich in anthocyanins, would affect OTA-treated rats. The current work sought to clarify the renal protective efficacy of RLE in an OTA-treated rat model (RLE (90 mg/kg b.w.); OTA (0.5 mg/kg b.w.)) by investigating, thorough Western blot analysis, the involvement of the Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. The OS parameters and inflammatory status were evaluated by spectrophotometry. The inflammatory infiltrates in the kidney were evaluated by immunohistochemical assays.
RESULTS AND CONCLUSION: Our findings showed a significant increase in oxidative and inflammatory parameters after OTA exposure, while the OTA + RLE co-treatment counteracted both the inflammatory and OS damage through the modulation of the Nrf2 pathway.
This invention relates generally to rubber products. In particular, but not necessarily restricted thereto, the present invention relates to rubber products which are handled or worn by human beings; more particularly, the present invention relates to a reduction of the effects of nitrosatable substances associated such rubber products. One skilled in the art will appreciate that the polymer contained in natural rubber latex and certain other rubber lattices can be cross-linked without prior coagulation as the product is, in effect, a latex of vulcanized rubber. In manufacturing industries, natural rubber latex is usually pre-vulcanized by heating with dispersions of sulphur and an accelerator, such as zinc diethyldithiocarbamate, to 50-80 °C. The reaction proceeds much more rapidly than the vulcanization of dry rubber at the same temperature with the same vulcanizing ingredients. However, certain ingredients used in manufacture of rubber products such as dithiocarbamate accelerators (vulcanization agents) and substances formed therefrom during vulcanisation are believed to react with nitrites present in human and animal body fluids to produce unacceptable levels of potentially carcinogenic nitrosamines. Furthermore, new constraints of a toxicological nature have appeared in recent years based on various national and regional regulations. The present invention seeks to provide an improved rubber composition. In particular, it seeks to provide a method of producing rubber products, especially those which come into contact with human and/ or animal body fluids which have a reduced tendency to produce nitrosamines during such contact.
The study is designed as a parallel, two-arm, non-blinded cluster-randomised controlled trial to be conducted in high-rise public housing estates in Singapore. The aim is to determine whether large-scale deployment of male Wolbachia-infected Ae. aegypti mosquitoes can significantly reduce dengue incidence in intervention clusters. The investigators will use the cluster-randomised design, with the study area comprising 15 clusters with a total area of 10.9 km2, covering approximately 722,000 residents in 1,700 apartment blocks. Eight clusters will be randomly selected to receive the intervention, while the other seven will serve as non-intervention clusters. Intervention efficacy will be estimated through two primary endpoints: (1) odds ratio of Wolbachia exposure distribution (i.e. probability of living in an intervention cluster) among laboratory-confirmed reported dengue cases compared to test-negative controls, and (2) laboratory-confirmed reported dengue counts normalized by population size in intervention versus non-intervention clusters.
Night Eating Syndrome (NES) is a unique disorder characterized by a delayed pattern of food intake in which recurrent episodes of food consumption occurs after the evening meal and/or during nocturnal awakenings. Diagnostic criteria for NES include: (1) recurrent episodes of night eating, as manifested by eating after awakening from sleep or by excessive food consumption following the evening meal, (2) awareness of those eating episodes, and (3) significant distress or impairment caused by the disorder. Exclusion criteria are binge-eating disorder or another mental disorder, as well as medical disorders or medications that might better explain the disordered eating pattern. NES is also more common among patients with insomnia, eating disorders, and other psychiatric disorders. 100 participants with night eating syndrome will be recruited from the general population. They will be randomized to either a commercially available rapid-release formulation of melatonin (5 mg) or matching placebo capsules, that will be administered once a day for a total of 8 weeks. Participants will attend a screening appointment, a baseline assessment and additional research assessment visits every other week for the 8 weeks.
PROBLEM TO BE SOLVED: To obtain the subject agent effective for dimorphic fungi existing normally in human body by including a compound having a specified geranyl group at the principal skeleton. SOLUTION: This agent includes at least one compound having a geranyl group of the formula (CH3)2C=CH-CH2-CH2-C(CH3)CH-CH2 (including α- and β-isomer) (preferably having terpenes in components). The terpenes are a terpene having one geranyl group as the principal skeleton (e.g. geraniol of formula I), a sesquiterpene including one geranyl group [e.g. α or β type farnesol (β-type of formula II)] or a diterpene including two geranyl groups (e.g. geranylgeraniol of formula III). In use of these compound as a transfer suppressing activator agent for dimorphic fungi, oral administration, hypodermic injection, intravenous injection, local administration and the like are all applicable.
Lantibiotics are synthesized on ribosomes as prepeptides and post-translationally modified to a mature form. These modifications include dehydrations and cyclizations. Compounds and related methods of generating compounds, modified by dehydration, cyclization, or dehydration and cyclization, are disclosed. The disclosure includes in vitro approaches to effecting dehydration and cyclization leading to production of biologically active compounds such as lantibiotics and variants thereof. Synthetic variants and methods including combinatorial approaches for generating diverse lantibiotics and other compounds are disclosed. The invention has broad potential for applications including food, agricultural, and medical industries.
The present invention relates to medicine for strengthening children and dispersing food, which is characterized in that the medicine is prepared from the following weight percentage of raw materials: the preparation of the medicine is an effervescent tablet; raw materials of Chinese herbal medicine comprise 10 to 18% of milk vetch, 5 to 9% of bran-fried atractylodes, 5 to 9% of orange peel, 10 to 18% of liriope, 5 to 9% of scutellaria, 5 to 9% of fried haws and 5 to 9% of fried raphanin; medical assistant materials comprise 20 to 25% of starch or dextrin, 5 to 9% of sodium bicarbonate and 2 to 5% of citric acid or fumaric acid or malic acid. The present invention also discloses a preparation method of the medicine. The medicine for strengthening children and dispersing food of the present invention adopts a novel effervescent tablet. The effervescent tablet is a solid preparation, and has the advantages of good stability, easy storage and convenient carrying and transportation. The preparation of the present invention does not contain a preservative, and establishes a content measuring method and a quality control standard thereof to make preparation quality controllable. The medicine of the present invention has the advantage of good mouth feel; the integral appearance of solution is elegant, is similar to carbonated drinks, and is easy to accept by child patients.
Participants will receive a text message everyday to build behavioral skills and practice self-monitoring of three behavior goals: (1) reduce TV time to less than 2 hours per day; (2) take 10,000 steps or more every day; (3) do 20 minutes or more of structures exercise like prenatal yoga or dance videos every day. Participants will also receive two health coaching mobile phone session; an introduction session and one problem solving session.
Participants will attend 3 training sessions per week at the RNOH. During these sessions, participants will tether their wheelchair (from under the seat) to the front of the iCycle, and their feet will be attached to the iCycle pedals. For training, participants will complete virtual reality cycle races displayed on a large screen in front of the iCycle: the more voluntary effort the participant contributes the greater the speed of the avatar. During cycling, a motor will control cycling speed, and muscle stimulation (FES) will be applied to the leg muscles (right and left gluteus, quadriceps and hamstrings) on alternative revolutions of the pedals. A dashboard screen will display controls for the stimulation, speed, brake, game switch and an emergency stop. Sessions will increase from 20 mins or the maximum achievable at the start (whichever is lower) up to at least 1 hour.
Treatment options for Alzheimer's disease (AD) remain limited, especially treatments linking neurovascular and neuroinflammatory changes with clinical manifestations of the disease. Prior research studies have documented a positive effect of cysteinyl leukotriene type 1 (cysLT-1) receptor antagonist, particularly Montelukast, on inflammatory processes in the brain and on neuronal injury, blood-brain-barrier (BBB) integrity, and amyloid-β42 (Aβ) protein accumulation. Although montelukast is currently in use for the treatment of inflammatory diseases e.g. bronchial asthma and exercise-induced bronchospasm, its effects on memory and thinking abilities and on AD biomarkers are yet to be fully understood.

This is a single site randomized controlled trial at Emory University that compares the effects of montelukast vs. placebo on memory and thinking abilities, as well as on brain imaging and markers of brain degeneration. Each participant will undergo a screening process following informed consent to determine if they meet study eligibility criteria. Participants will be enrolled in the study for 1 year.